The field of genomics is expanding so rapidly that to find a niche companies are moving into areas that traditionally have been difficult to study with molecular tools. GenoPlex Inc. sees such an opening into fresh territory, and is applying structural and functional genomics in mice and nematodes for gene discovery through target validation in neural and behavioral health, with programs in learning and memory, aging, and response to anesthetics and alcohol.

"As a genomics company, we didn't want to be in an area that everybody is in," said Kenneth Collins, president and CEO. "There's no question that learning and memory and aging are complex and a bit further out there, but we have developed a rigorous approach, and we think it's an appropriate time to bring it to industry."